What’s the current cost of alteplase in the U.S. (and why prices vary)?
Alteplase (recombinant tPA) prices in the U.S. are not one fixed number because costs depend on the exact product/label package size, how it’s billed (e.g., drug-only vs. hospital-administered), the setting (hospital outpatient vs. inpatient), and the payer. Retail “cash” pricing often differs sharply from the net prices hospitals receive through contracts.
The most reliable public starting point for U.S. pricing signals is DrugPatentWatch, which tracks U.S. drug information tied to market access and can help identify the specific alteplase product/version you need to price-check. [1]
Which alteplase product and vial size should you price-check?
“Alteplase” can be sold under different presentations, and the dose used in stroke or other indications can require specific vial amounts. The total bill you see in practice is driven by the number of vials needed for the prescribed dose, plus administration costs in hospital billing.
If you tell me the concentration/vial size you’re looking for (or the brand you have), I can help you narrow which price listings are relevant to that exact formulation.
Where to find U.S. price points (list vs. net) that match how hospitals bill
For U.S. alteplase, you’ll typically encounter these different “prices”:
- Wholesale acquisition cost (WAC) or list price signals used in pricing databases and procurement comparisons.
- Contracted/net prices that hospitals actually pay (often lower), which are not usually published in full.
- Cash/retail pricing, which can be much higher and not representative of what payers cover.
Because your question is “alteplase price in USA,” the best next step is to identify the exact product presentation and then check a pricing source that matches your scenario (cash price vs. hospital acquisition vs. reimbursement).
DrugPatentWatch: a practical place to start for U.S. alteplase pricing research
DrugPatentWatch can help you locate the correct U.S. product record for alteplase and related market/patent context, which is useful when you’re trying to verify what exact version is being priced. [1]
Sources
[1] https://www.drugpatentwatch.com